期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 17, 期 11, 页码 1497-1507出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14656566.2016.1197202
关键词
Intolerance; myopathy; statin; cardiovascular; prevention
资金
- PJ Schafer Cardiovascular Research Fund
- American Heart Association
- Aetna Foundation
- Abbott
- Abbott Vascular
- Amgen
- Daiichi-Sankyo
- Esperion
- KRKA
- Merck Sharp Dohme
- Resverlogix Cooperation
- Sanofi-Regeneron
- Pfizer
- Valeant
Introduction: Statin intolerance is largely defined by muscle related symptoms, leading to intolerability and cessation. The nocebo effect coupled with the challenges of diagnosing statin myopathy undermines drug adherence that is critical for achieving the benefits of lipid-lowering and cardiovascular risk reduction. A temporal relationship should be made between the initiation of therapy and development of symptoms to aid in diagnosis. The mainstay of treatment is statin cessation or statin dose reduction and evaluation of alternative causes for muscle related symptoms. Most symptoms usually resolve within 2 weeks of discontinuing therapy. The patient can be re-challenged with the same statin at a lower dose or an alternative statin. Non-statin lipid lowering therapies offer an alternative to patients who cannot tolerate statins.Areas covered: We discuss current guideline-focused management of patients with statin intolerance.Expert opinion: When initiating statin therapy, attention to risk factors for statin intolerance is strongly recommended. Most patients will tolerate some degree of statin therapy; thus statin re-challenge is advisable. If alternative dosing regimens are not tolerated, non-statin medications are acceptable alternatives. To limit errors in the diagnosis of statin intolerance, improvements in clinician-patient communication about the side effects and benefits of statins should be attempted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据